Skip to main content
. 2021 Dec 20;23(2):e53865. doi: 10.15252/embr.202153865

Figure 4. Intranasal application of NM1267 protects K18‐hACE2 mice against SARS‐CoV‐2 B.1‐induced disease and reduces mortality and virus shedding.

Figure 4

  • A
    Schematic illustration of treatment scheme.
  • B, C
    Hemizygous K18‐hACE2 mice were treated intranasally with 20 µg of NM1251 (n = 15) or NM1267 (n = 12) 7 h prior to infection with 3 × 103 PFU SARS‐CoV‐2 B.1. Weight loss (B) and survival (C) were monitored for 14 days.
  • D
    Nasal swabs were collected from six mice per group (n = 6) at the indicated time points and viral load was determined by plaque‐assay.

Data information: Dashed line indicates humane end point in (B) and symbols represent mean ± SEM in (B) or individual animals in (D). Bars in (D) represent mean ± SEM. ****P < 0.0001, by two‐way ANOVA with Sidak's multiple comparison test in (B), ****P < 0.0001, by log‐rank test in (C), and **P < 0.01, by unpaired t‐test in (D).